ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide, and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide, offer a biologically plausible mechanism for targeting metabolic dysfunction in PMOS. This review examines clinical trial evidence on the anthropometric and metabolic effects of incretin-based therapies in this population, including a focus on women of reproductive age, who face distinct challenges related to preconception planning, treatment duration, and post-discontinuation metabolic and weight management. Available literature shows that liraglutide, semaglutide and tirzepatide produce clinically meaningful reductions in body weight, body mass index (BMI), and waist circumference, with some studies also confirming preferential effects on visceral and ectopic fat compartments. Glycaemic and insulin resistance outcomes vary across studies, while lipid and blood pressure effects remain incompletely characterized. Although emerging data suggest that higher-potency agents may yield more consistent weight-loss benefits, available PMOS-specific evidence does not establish comparative metabolic superiority among agents. Interpretation of the available evidence is limited by the predominance of short-term trials at sub-obesity doses, frequent co-administration with metformin, and the absence of phenotype-stratified data, leaving the full metabolic potential of these agents in PMOS incompletely defined. Larger, longer, and higher-dose trials are needed to fully characterize the anthropometric and metabolic potential of these agents in PMOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.